Updated:
Fractyl Health
Fractyl Health went public in 2024 with a gene therapy platform targeting metabolic disease at the organ level. Founded by cardiologists in 2010.
Fractyl Health
Fractyl Health was launched in 2010 by Harith Rajagopalan and Jay Caplan, two cardiologists who believed the standard approach to type 2 diabetes was treating the symptom, not the disease. The company spent its first decade developing and commercializing Revita, an endoscopic duodenal mucosal resurfacing procedure that alters the gut lining to restore metabolic function. In 2024 Fractyl priced an IPO on the Nasdaq under the ticker GUTS, raising $110M, and pivoted its pipeline toward a pancreatic gene therapy platform designed to reverse obesity and diabetes permanently. The firm's strategy splits across two programs. Revita targets the duodenum's dysfunctional lining — essentially resetting the gut-brain signaling that drives insulin resistance — while the preclinical Rejuva platform injects a gene therapy directly into the pancreas to regenerate insulin-producing cells. The company has treated patients in clinical trials across the United States and Europe, and its Revita system received a CE mark in Europe for type 2 diabetes. Key clinical data sets include the REVITA-2 pivotal study in the US and real-world registries in Germany. Fractyl does not operate as a fund; it is a clinical-stage operating company whose deployment is R&D spend and clinical trial execution. Fractyl is lean by medical-device standards — its public filings show a team concentrated in Burlington, Massachusetts, with most capital directed toward the Rejuva gene therapy platform since the 2024 IPO. The company is not a family office or asset manager; it functions as a pure-play biotech, though its capital allocation decisions have drawn attention from crossover healthcare funds and metabolic-focused institutional allocators. September 2024: Fractyl Health reported positive preclinical data for its Rejuva gene therapy candidate in non-human primates, demonstrating durable weight loss and glucose control (per the firm, September 2024). The structural differentiator is disease-modifying intent. Most diabetes interventions — drugs, devices, surgery — manage the condition. Fractyl's architecture aims for one-time curative intervention, first via a scope-based procedure and now via gene therapy. If Rejuva succeeds clinically, the company shifts from a reflux-and-diabetes device maker into a gene-editing platform competing with Vertex and CRISPR Therapeutics in the metabolic space — a rare arc for a $200M market-cap biotech.
General information
Firm type
Asset Manager
Year founded
2010
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Burlington
Corporate office
Burlington, MA, United States
Principals
Harith Rajagopalan
Chief Executive Officer
Jay Caplan
Chief Financial Officer
Sector focus
Frequently asked questions
Is Fractyl Health a single-family office or an operating company?
Fractyl Health is a clinical-stage biotechnology operating company, not a family office. It was founded in 2010, went public on the Nasdaq in 2024 (ticker: GUTS), and deploys its capital into R&D and clinical trials for metabolic disease therapies. The firm does not manage outside capital for a family or run a fund-of-funds program.
What is Fractyl's pancreatic gene therapy platform, and how does it work?
The Rejuva platform uses an adeno-associated viral vector to deliver a gene directly to the pancreas, aiming to regenerate insulin-producing beta cells. In preclinical non-human primate studies reported in September 2024, the therapy demonstrated durable weight loss and normalization of glucose control. This moves Fractyl beyond its original duodenal resurfacing device into the gene therapy arena.
How does Revita differ from standard diabetes drugs like GLP-1 agonists?
Revita is an endoscopic procedure that thermally ablates the dysfunctional duodenal lining, altering gut hormone signaling to improve insulin sensitivity. Unlike GLP-1 agonists, which require ongoing injections, Revita aims to be a one-time intervention. The device received CE mark approval in Europe for type 2 diabetes, though US pivotal trial data will determine its regulatory path.
Who runs investment and capital allocation decisions at Fractyl Health?
As a public operating company, Fractyl's capital allocation is overseen by CEO Harith Rajagopalan and CFO Jay Caplan, with ultimate oversight from the board of directors. The company's primary deployment is into its own clinical programs — Revita and Rejuva — rather than external investments. All material capital decisions are disclosed in SEC filings.
What investment stages do institutional allocators participate in with Fractyl?
Institutional allocators participate in Fractyl through public equity holdings (Nasdaq: GUTS) or earlier venture rounds prior to the 2024 IPO. The company raised crossover rounds from healthcare-dedicated funds before the public listing. Allocators cannot invest directly in Fractyl's clinical programs as limited partners; participation is limited to the company's equity.
Where does Fractyl Health's valuation sit relative to its metabolic biotech peers?
As of mid-2025, Fractyl trades at a market capitalization near $200M, significantly below gene therapy peers like Vertex Pharmaceuticals or CRISPR Therapeutics, despite holding a similarly ambitious disease-modifying approach. The valuation gap reflects the company's preclinical Rejuva data and the uncertainty around Revita's US pivotal trial outcome.
Does Fractyl Health maintain any philanthropic or nonprofit structures?
Public records do not indicate a Fractyl-branded philanthropic foundation or donor-advised fund. The company's charitable activity, if any, would be disclosed in SEC filings or standalone corporate social responsibility reports, though none have been identified as of mid-2025.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: